Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants.

[1]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[2]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.

[3]  K. Hoadley,et al.  Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. , 2017, European urology.

[4]  T. Ørntoft,et al.  Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer , 2017, Scientific Reports.

[5]  M. Höglund,et al.  Molecular classification of urothelial carcinoma: global mRNA classification versus tumour‐cell phenotype classification , 2017, The Journal of pathology.

[6]  J. Weinstein,et al.  Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. , 2016, European urology.

[7]  B. Taylor,et al.  Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer , 2016, Nature Genetics.

[8]  Katherine A. Hoadley,et al.  Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology , 2014, Proceedings of the National Academy of Sciences.

[9]  K. Baggerly,et al.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. , 2014, Cancer cell.

[10]  M. Ringnér,et al.  A Molecular Taxonomy for Urothelial Carcinoma , 2012, Clinical Cancer Research.